MW390A1 - Antiviral or antibacterial compound and method of use - Google Patents

Antiviral or antibacterial compound and method of use

Info

Publication number
MW390A1
MW390A1 MW3/90A MW390A MW390A1 MW 390 A1 MW390 A1 MW 390A1 MW 3/90 A MW3/90 A MW 3/90A MW 390 A MW390 A MW 390A MW 390 A1 MW390 A1 MW 390A1
Authority
MW
MALAWI
Prior art keywords
antiviral
composition
disclosed
antibacterial compound
forms
Prior art date
Application number
MW3/90A
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of MW390A1 publication Critical patent/MW390A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

A composition having antiviral and antibacterial effects is disclosed which comprises the dimeric forms of enzymes selected from lysozyme and ribonuclease and a pharmaceutically acceptable carrier. These dimeric forms are more effective in treating a variety of human and animal diseases because they are much less cytotoxic than the monomeric forms of the enzyme. A method for the use of these compositions is also disclosed which comprises applying an effective amount of the composition to the infected area.
MW3/90A 1988-05-26 1990-01-22 Antiviral or antibacterial compound and method of use MW390A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17858888A 1988-05-26 1988-05-26
PCT/US1988/001785 WO1989011294A1 (en) 1988-05-26 1988-05-26 Antiviral or antibacterial compound and method of use
OA59731A OA09785A (en) 1988-05-26 1990-01-26 Antiviral or antibacterial compound and method of use

Publications (1)

Publication Number Publication Date
MW390A1 true MW390A1 (en) 1990-11-14

Family

ID=33162813

Family Applications (1)

Application Number Title Priority Date Filing Date
MW3/90A MW390A1 (en) 1988-05-26 1990-01-22 Antiviral or antibacterial compound and method of use

Country Status (23)

Country Link
US (3) US5200182A (en)
EP (1) EP0380484B1 (en)
JP (1) JPH0649659B2 (en)
AT (1) ATE93143T1 (en)
AU (1) AU624331B2 (en)
BG (1) BG60544B1 (en)
CA (1) CA1335425C (en)
CS (1) CS277030B6 (en)
DK (1) DK173078B1 (en)
ES (1) ES2011577A6 (en)
FI (1) FI900412A0 (en)
HK (1) HK42394A (en)
HU (1) HU204710B (en)
IL (1) IL90092A (en)
LV (1) LV10054B (en)
MA (1) MA21560A1 (en)
MW (1) MW390A1 (en)
OA (1) OA09785A (en)
PH (1) PH26284A (en)
RU (1) RU2092183C1 (en)
WO (1) WO1989011294A1 (en)
YU (1) YU109289A (en)
ZA (1) ZA893382B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU624331B2 (en) * 1988-05-26 1992-06-11 Nika Health Products Ltd. A composition having as its active ingredient lysozyme or ribonuclease dimer in a pharmaceutically acceptable carrier
RU2067617C1 (en) * 1990-01-08 1996-10-10 Ника Хелт Продактс Лтд. Method of lysozyme dimer preparing
US5989880A (en) 1990-01-08 1999-11-23 Nika Health Products Ltd. Method of preparing lysozyme dimers
PL173978B1 (en) * 1992-07-13 1998-05-29 Nika Health Products Ltd Method of obtaining a preparation capable to retard the synthesis of endogenous cytotoxic cytokinins
CH682541A5 (en) * 1992-06-23 1993-10-15 Urs Viktor Dr Wirth Biochemical Inactivation of RNA viruses.
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (en) * 1995-01-13 2002-10-15 Nika Health Products Ltd New applications of a lysozyme dimer.
GB2304048A (en) * 1995-08-12 1997-03-12 John William Carson Medicament containing saliva extract
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
JP2002187853A (en) * 2000-12-21 2002-07-05 Shinei Ferumentekku:Kk Disinfectiong agent for nipple of animal, and method for improving fungal environment
DE10210285A1 (en) * 2002-03-08 2003-11-13 Medigene Ag Reversible toxin and its use
JP2008505853A (en) * 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド Non-natural ribonuclease complex as a cytotoxic agent
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US7348301B2 (en) * 2006-02-16 2008-03-25 Buckman Laboratories International, Inc. Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease
JP2009543868A (en) 2006-07-17 2009-12-10 クインテセンス バイオサイエンシーズ インコーポレーティッド Methods and compositions for cancer treatment
WO2008109401A2 (en) * 2007-03-02 2008-09-12 Saint Simeon Lda Composition and method for treating papilloma virus and equine sarcoids
US20100317677A1 (en) * 2007-09-11 2010-12-16 Hassel Bret A Methods of Treating a Microbial Infection by Modulating RNase-L Expression and/or Activity
CA2702043A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
JP2012504423A (en) 2008-10-01 2012-02-23 クインテッセンス バイオサイエンシズ，インコーポレーテッド Therapeutic ribonuclease
WO2010099182A1 (en) * 2009-02-25 2010-09-02 Board Of Regents Of The University Of Nebraska Activated creatinine and precursors as antibacterial agents, compositions and products containing such agents and uses thereof
NZ600269A (en) 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
EP2457576B1 (en) 2010-11-29 2020-07-08 Eurochit Danuta Kruszewska Lactobacillus reuteri strain for use in the medical and veterinary prophylaxis and treatment of metabolic syndrome or infections
RU2548803C2 (en) * 2011-11-28 2015-04-20 Общество с ограниченной ответственностью " Фарматренд" PHARMACEUTICAL COMPOSITION FOR TREATING EYE INFECTIONS P. Aeruginosa CONTAINING RECOMBINANT LYSOZYME
RU2509801C2 (en) * 2012-03-22 2014-03-20 Борис Михайлович Куриненко METHOD OF USING Bacillus intermedius RIBONUCLEASE
EP2674162A1 (en) 2012-05-29 2013-12-18 Danuta Kruszewska Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same
CN104684565A (en) 2012-05-29 2015-06-03 达努塔·克鲁谢夫斯卡 Nanoproduct comprising Lactobacillus reuteri DAN080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same
RU2504397C1 (en) * 2012-10-25 2014-01-20 Леонид Леонидович Клопотенко Pharmaceutical composition containing enzyme ribonuclease and glycyrrhizic acid or salts thereof: ammonium or dipotassium or trisodium glycyrrhizinate
US9950075B2 (en) 2013-03-15 2018-04-24 The University Of Massachusetts Compositions and methods for delivering agents to the central nervous system
US9573980B2 (en) 2013-03-15 2017-02-21 Spogen Biotech Inc. Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
CN106029089B (en) * 2014-02-21 2020-12-29 丘比株式会社 Norovirus inactivator and method for producing same
SG11201700611TA (en) * 2014-07-31 2017-02-27 Kewpie Corp Water-containing fluid composition, method for producing same, processed lysozyme and/or salt thereof, and method for producing same
NZ767896A (en) 2014-09-17 2024-01-26 Spogen Biotech Inc Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
LV15071B (en) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Composition for treatment of subclinical mastitis in cows
RU2634264C1 (en) * 2016-09-19 2017-10-24 Александр Ливиевич Ураков Cream-milk for zoster treatment
JP6547915B2 (en) 2016-12-28 2019-07-24 Dic株式会社 Dispersion, ink composition for inkjet using the same, light conversion layer, and liquid crystal display device
WO2021021765A1 (en) * 2019-07-26 2021-02-04 Evolve Biosystems, Inc. Nutritive compositions with bioactive proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1268M (en) * 1961-06-29 1962-04-24 Puiseux Antimitotic and antiviral drug.
FR4020M (en) * 1965-01-29 1966-03-21
DE1517751C3 (en) * 1965-07-08 1975-02-27 Eisai Co., Ltd., Tokio Method for preventing the formation of flaky lysozyme and / or lysozyme salt precipitates in aqueous solutions containing lysozyme and / or lysozyme salts
DE1545644A1 (en) * 1965-12-06 1969-08-07 Boehringer Sohn Ingelheim Process for the preparation of new quaternary scopolammonium salts
GB1110504A (en) * 1966-03-18 1968-04-18 Prodotti Antibiotici Spa Pharmaceutical compositions
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
CA1263378A (en) * 1985-01-08 1989-11-28 Robert James Alaimo Imidazo¬4,5-f|quinolines useful as immunomodulating agents
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
AU624331B2 (en) * 1988-05-26 1992-06-11 Nika Health Products Ltd. A composition having as its active ingredient lysozyme or ribonuclease dimer in a pharmaceutically acceptable carrier

Also Published As

Publication number Publication date
DK16890D0 (en) 1990-01-22
LV10054A (en) 1994-05-10
ES2011577A6 (en) 1990-01-16
ZA893382B (en) 1991-01-30
WO1989011294A1 (en) 1989-11-30
HU883981D0 (en) 1990-12-28
US6099835A (en) 2000-08-08
RU2092183C1 (en) 1997-10-10
US5466449A (en) 1995-11-14
FI900412A0 (en) 1990-01-25
PH26284A (en) 1992-04-10
CS277030B6 (en) 1992-11-18
IL90092A (en) 1995-03-30
AU1940888A (en) 1989-12-12
YU109289A (en) 1991-08-31
JPH0649659B2 (en) 1994-06-29
JPH03504121A (en) 1991-09-12
LV10054B (en) 1995-02-20
AU624331B2 (en) 1992-06-11
HUT54060A (en) 1991-01-28
BG60544B1 (en) 1995-08-28
HK42394A (en) 1994-05-13
CA1335425C (en) 1995-05-02
DK173078B1 (en) 1999-12-20
HU204710B (en) 1992-02-28
EP0380484A1 (en) 1990-08-08
US5200182A (en) 1993-04-06
EP0380484B1 (en) 1993-08-18
CS318089A3 (en) 1992-05-13
OA09785A (en) 1994-04-15
DK16890A (en) 1990-01-22
MA21560A1 (en) 1989-12-31
ATE93143T1 (en) 1993-09-15

Similar Documents

Publication Publication Date Title
MW390A1 (en) Antiviral or antibacterial compound and method of use
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
MY110734A (en) Improvements in or relating to dioic acids.
IL84510A (en) Agents for combating pests and plant treatment agents consisting of microorganism granulates
ES2160643T3 (en) COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF.
ZA898605B (en) Compositions for topical treatment of skin diseases
ZA929947B (en) Method of imparting antimicrobial activity to an opthalmic composition.
JO1610B1 (en) Antiviral tetrahydroimidazo (1,4) benzodiazepin -2- thiones
MX9706689A (en) Treatment of cytokine growth factor caused disorders.
AU2840889A (en) Method of treating haematologic diseases and pharmaceutical compositions to be used therefor
JO1589B1 (en) Antiviral tetrahydroimidazo(1,4)benzodiazepin-2-ones
MY106984A (en) Antiviral or antibacterial composition and method of use.
AU591017B2 (en) Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof
AU6600190A (en) Therapeutic compositions; methods for treatment of hiv infections
GR1001006B (en) Method for preparating and using antimicrobiac or antibacterial compositions
AU3575189A (en) Long lasting composition of propafenone and quinidine for treatment of cardiac conditions
AU2314488A (en) Anthelmintic acylhydrazones, method of use and compositions
MX9307639A (en) METHOD FOR TREATING VIRAL INFECTIONS WITH CONJUNCTIVE THERAPY WITH COMPOUNDS SIMILAR TO ACICLOVIR AND AN ANALOGUE OF 2'-VIRIL SUBSTITUTED NUCLEOSIDE.
MY104932A (en) Immunomodulatory azaspiranes
HRP930588B1 (en) Process for the preparation of therapeutic transdermal system having physostigmine as an active ingredient
MX9605327A (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration.